» Articles » PMID: 24135280

EGFR Phosphorylates Tumor-derived EGFRvIII Driving STAT3/5 and Progression in Glioblastoma

Overview
Journal Cancer Cell
Publisher Cell Press
Specialty Oncology
Date 2013 Oct 19
PMID 24135280
Citations 157
Authors
Affiliations
Soon will be listed here.
Abstract

EGFRvIII, a frequently occurring mutation in primary glioblastoma, results in a protein product that cannot bind ligand, but signals constitutively. Deducing how EGFRvIII causes transformation has been difficult because of autocrine and paracrine loops triggered by EGFRvIII alone or in heterodimers with wild-type EGFR. Here, we document coexpression of EGFR and EGFRvIII in primary human glioblastoma that drives transformation and tumorigenesis in a cell-intrinsic manner. We demonstrate enhancement of downstream STAT signaling triggered by EGFR-catalyzed phosphorylation of EGFRvIII, implicating EGFRvIII as a substrate for EGFR. Subsequent phosphorylation of STAT3 requires nuclear entry of EGFRvIII and formation of an EGFRvIII-STAT3 nuclear complex. Our findings clarify specific oncogenic signaling relationships between EGFR and EGFRvIII in glioblastoma.

Citing Articles

Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation.

Sun F, Yao F, Zeng C, Zhao Y, Liang B, Li S J Immunother Cancer. 2025; 13(2).

PMID: 39947814 PMC: 11831272. DOI: 10.1136/jitc-2024-010126.


PCBP2-dependent secretion of miRNAs via extracellular vesicles contributes to the EGFR-driven angiogenesis.

Xia H, Wang X, Zhang H, Wang K, Zhang L, Yang Y Theranostics. 2025; 15(4):1255-1271.

PMID: 39816681 PMC: 11729547. DOI: 10.7150/thno.102391.


CYP3A5 promotes glioblastoma stemness and chemoresistance through fine-tuning NAD/NADH ratio.

Hu W, Cui X, Liu H, Li Z, Chen X, Wang Q J Exp Clin Cancer Res. 2025; 44(1):3.

PMID: 39754188 PMC: 11697892. DOI: 10.1186/s13046-024-03254-x.


Bioinformatics Identification of angiogenesis-related biomarkers and therapeutic targets in cerebral ischemia-reperfusion.

Wu Y, Sun J, Huang J, Lu X Sci Rep. 2024; 14(1):32096.

PMID: 39738531 PMC: 11685884. DOI: 10.1038/s41598-024-83783-9.


Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications.

Hashemi M, Abolghasemi Fard A, Pakshad B, Asheghabadi P, Hosseinkhani A, Hosseini A Noncoding RNA Res. 2024; 11:1-21.

PMID: 39720352 PMC: 11665378. DOI: 10.1016/j.ncrna.2024.11.006.


References
1.
Jura N, Endres N, Engel K, Deindl S, Das R, Lamers M . Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell. 2009; 137(7):1293-307. PMC: 2814540. DOI: 10.1016/j.cell.2009.04.025. View

2.
Inda M, Bonavia R, Mukasa A, Narita Y, Sah D, Vandenberg S . Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010; 24(16):1731-45. PMC: 2922502. DOI: 10.1101/gad.1890510. View

3.
Luwor R, Zhu H, Walker F, Vitali A, Perera R, Burgess A . The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene. 2004; 23(36):6095-104. DOI: 10.1038/sj.onc.1207870. View

4.
Fan Q, Weiss W . RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. Oncogene. 2004; 24(5):829-37. DOI: 10.1038/sj.onc.1208227. View

5.
Johns T, Perera R, Vernes S, Vitali A, Cao D, Cavenee W . The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res. 2007; 13(6):1911-25. DOI: 10.1158/1078-0432.CCR-06-1453. View